AML	Acute myeloid leukemia
KMT2A	Histone-lysine N-methyltransferase 2A
KMT2A-r	KMT2A rearrangements
NPM1	Nucleophosmin 1
NPM1-m	NPM1 mutated
HOX	Homeobox
MEIS1	Myeloid ecotropic virus insertion site 1
MLL	Mixed-lineage leukemia
H3K4	Histone three lysine 4
SET	Su(var)3–9, Enhancer of zester and Trithorax
WDR5	WD repeat protein 5
RbBP5	Retinoblastoma binding protein 5
HSC	Hematopoietic stem cell
EAP	Eleven Nineteen Leukemia-associated protein
ALL	Acute lymphoblastic leukemia
NES	Nuclear export signals
NLS	Nuclear localization signal
NoLS	Nucleolar localization signal
HDM2	Human double minute 2
LEDGF	Lens epithelium-derived growth factor
SUV39H1	Suppressor of variegation 3–9 homolog 1
R/R	Relapsed/refractory
CYP3A4	Cytochrome P450 3A4
Cmax	Maximum plasma concentration
Tmax	Time to peak
AUC	Area under curve
CNS	Central nervous system
FDA	Food and Drug Administration
HCT	Hematopoietic cell transplant
ORR	Overall response rate
CR	Complete response
CRh	Complete response with partial hematologic recovery
MRD	Minimal residual disease
OS	Overall survival
CRc	Composite complete response
EFS	Event free survival
RFS	Relapse free survival
BAMT	Beat AML Master Trial
NGS	Next generation sequencing
TEAE	Treatment emergent adverse events
DS	Differentiation syndrome
ELN	European Leukemia Net
DLT	Dose limiting toxicity
MLFS	Morphologic leukemia free state
DL	Dose level
NR	Not reached